UNDERSTANDING PSILOCYBIN ADMINISTRATION: DOSE, PARTICIPANT CHARACTERISTICS, AND THERAPEUTIC CONTEXT

Background

Psilocybin shows promise for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), yet the interplay between pharmacological dose, individual patient characteristics, and therapeutic context during psilocybin administration warrants ongoing research. Understanding these factors is critical for the scalable and accessible real-world delivery of psilocybin treatment.

Methods

In Study 1, hierarchical regression assessed how pre-treatment participant characteristics and dose (25mg, 10mg, or 1mg COMP360 psilocybin [a proprietary, pharmaceutical-grade synthetic psilocybin formulation, developed by Compass Pathfinder Ltd.]) predicted subjective psychedelic experience in 233 adults with treatment-resistant depression (ClinicalTrials.gov NCT03775200). In a subset of 101 participants from Study 1, Study 2 used natural language processing (NLP) of session transcripts to predict clinical response (≥50% MADRS reduction) from linguistic sentiment, psychedelic experience, and dose. In Study 3, transcripts from 22 participants with PTSD receiving 25 mg COMP360 psilocybin (ClinicalTrials.gov NCT05312151) were analyzed for words-per-minute (WPM) by participant and support provider during preparation, administration, and follow-up sessions to characterize support and engagement patterns.

Results

In Study 1, COMP360 dose was the strongest predictor of subjective psychedelic experience, while the pre-treatment individual characteristics showed only modest associations across experiential domains. In Study 2, linguistic sentiment and participant emotional breakthrough predicted clinical response with 85–88% accuracy, such that the stronger emotional experiences correlated with greater symptom reduction. In Study 3, administration sessions were characterized by 78% silence versus 25–30% in nonadministration sessions. Providers’ speech density was less variable than that of participants across all sessions, consistent with adherence to standardized training.

Conclusions

Taken together, these findings indicate that the psychedelic experience during psilocybin administration is immersive and internally driven, shaped primarily by the pharmacological dose, and that the consequent strong emotional experience may contribute to positive treatment outcomes. Future research is warranted to confirm the utility of these tools and the current findings.

References

Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022;387(18):1637-48. Dougherty RF, Clarke P, Atli M, et al. Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. Psychopharmacology. 2025;242(7):1553-61.